{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T13:38:38Z","timestamp":1776087518931,"version":"3.50.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T00:00:00Z","timestamp":1760400000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T00:00:00Z","timestamp":1760400000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002551","name":"Seoul National University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002551","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Diffuse large B-cell lymphoma (DLBCL) outcomes decline in patients aged\u2009\u2265\u200980 years, with R-CHOP as standard therapy despite frequent dose reductions due to frailty. This study evaluates treatment outcomes and prognostic factors, including the Geriatric Nutritional Risk Index (GNRI), in this population.\u00a0We retrospectively analyzed 102 patients aged\u2009\u2265\u200980 years with newly diagnosed DLBCL treated with full-dose or dose-attenuated R-CHOP at Seoul National University Bundang Hospital (2005\u20132024). Baseline characteristics, treatment delivery, toxicities, and survival were assessed using Kaplan-Meier methods and Cox proportional hazards models.\u00a0Median age was 83 years; 57.8% had advanced-stage disease, and 55.8% were high\/high-intermediate IPI risk. Median relative dose intensity was 54.0%; 65.7% completed treatment. Grade 3\u20134 toxicities occurred in 33.3%. At 2 years, overall survival (OS) was 71.8% and progression-free survival (PFS) was 67.2%. In multivariate analysis, low GNRI (&lt;\u200981.6) independently predicted worse OS (HR 3.09, 95% CI 1.40\u20136.82,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.005) and PFS (HR 2.84, 95% CI 1.34\u20136.02,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.006); IPI\u2009\u2265\u20093 was associated with inferior PFS (HR 2.11, 95% CI 1.03\u20134.32,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.042). The composite GNRI-IPI score stratified OS and PFS effectively, with high-risk showing worse survival (OS: HR 6.44, 95% CI 2.45\u201316.93,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.001; PFS: HR 6.00, 95% CI 2.42\u201314.92,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.001) and higher grade 3\u20134 toxicities (63.6% vs. 22.0% in low-risk,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.023).\u00a0GNRI-IPI enhances risk stratification and toxicity prediction in very elderly DLBCL patients, supporting nutritional integration in prognostication. Prospective validation is warranted.\n                  <\/jats:p>","DOI":"10.1007\/s00277-025-06670-x","type":"journal-article","created":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T04:03:57Z","timestamp":1760414637000},"page":"5867-5879","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Prognostic impact of GNRI-IPI score in octogenarians with diffuse large B-Cell lymphoma treated with R-CHOP"],"prefix":"10.1007","volume":"104","author":[{"given":"Eun-Jeong","family":"Jeong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Woochan","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeongmin","family":"Seo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minsu","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eun Hee","family":"Jung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sang-A","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koung Jin","family":"Suh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji-Won","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Se Hyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeong-Ok","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin Won","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu Jung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keun-Wook","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jee Hyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jong Seok","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soo-Mee","family":"Bang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji Yun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,14]]},"reference":[{"issue":"20","key":"6670_CR1","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","volume":"127","author":"SH Swerdlow","year":"2016","unstructured":"Swerdlow SH et al (2016) The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 127(20):2375\u20132390","journal-title":"Blood"},{"issue":"1","key":"6670_CR2","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1182\/blood-2005-06-2508","volume":"107","author":"LM Morton","year":"2006","unstructured":"Morton LM et al (2006) Lymphoma incidence patterns by WHO subtype in the United States, 1992\u20132001. Blood 107(1):265\u2013276","journal-title":"Blood"},{"issue":"4","key":"6670_CR3","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1056\/NEJMoa011795","volume":"346","author":"B Coiffier","year":"2002","unstructured":"Coiffier B et al (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346(4):235\u2013242","journal-title":"N Engl J Med"},{"issue":"5","key":"6670_CR4","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/S1470-2045(06)70664-7","volume":"7","author":"M Pfreundschuh","year":"2006","unstructured":"Pfreundschuh M et al (2006) CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera international trial (MInT) group. Lancet Oncol 7(5):379\u2013391","journal-title":"Lancet Oncol"},{"issue":"2","key":"6670_CR5","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/S1470-2045(08)70002-0","volume":"9","author":"M Pfreundschuh","year":"2008","unstructured":"Pfreundschuh M (2008) Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20\u2009+\u2009B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol 9(2):105\u2013116","journal-title":"Lancet Oncol"},{"issue":"2","key":"6670_CR6","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1002\/onco.13610","volume":"26","author":"M Di","year":"2021","unstructured":"Di M, Huntington SF, Olszewski AJ (2021) Challenges and opportunities in the management of diffuse large B-cell lymphoma in older patients. Oncologist 26(2):120\u2013132","journal-title":"Oncologist"},{"issue":"4","key":"6670_CR7","doi-asserted-by":"publisher","first-page":"525","DOI":"10.3324\/haematol.2014.107300","volume":"100","author":"DE Issa","year":"2015","unstructured":"Issa DE et al (2015) Trends in incidence, treatment and survival of aggressive B-cell lymphoma in the Netherlands 1989\u20132010. Haematologica 100(4):525\u2013533","journal-title":"Haematologica"},{"issue":"1","key":"6670_CR8","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1111\/bjh.16737","volume":"192","author":"K Sonnevi","year":"2021","unstructured":"Sonnevi K (2021) Survival of very elderly patients with diffuse large B-cell lymphoma according to treatment intensity in the immunochemotherapy era: a Swedish lymphoma register study. Br J Haematol 192(1):75\u201381","journal-title":"Br J Haematol"},{"issue":"10","key":"6670_CR9","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1182\/bloodadvances.2016002675","volume":"1","author":"U Giri","year":"2017","unstructured":"Giri U, Martin MG (2017) Survival outcomes in the very elderly with DLBCL prior to and after the introduction of rituximab: a US population-based study. Blood Adv 1(10):615\u2013618","journal-title":"Blood Adv"},{"issue":"5","key":"6670_CR10","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/S1470-2045(11)70069-9","volume":"12","author":"F Peyrade","year":"2011","unstructured":"Peyrade F (2011) Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial. Lancet Oncol 12(5):460\u2013468","journal-title":"Lancet Oncol"},{"key":"6670_CR11","unstructured":"Network NCC (2025) NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae): B-Cell Lymphomas. Version 2.2025."},{"issue":"8","key":"6670_CR12","doi-asserted-by":"publisher","first-page":"e344","DOI":"10.1016\/S1470-2045(12)70234-6","volume":"13","author":"F Peyrade","year":"2012","unstructured":"Peyrade F (2012) Treatment decisions for elderly patients with haematological malignancies: a dilemma. Lancet Oncol 13(8):e344\u2013e352","journal-title":"Lancet Oncol"},{"issue":"21","key":"6670_CR13","first-page":"2566","volume":"141","author":"PJ Lugtenburg","year":"2023","unstructured":"Lugtenburg PJ, Mutsaers P (2023) How i treat older patients with DLBCL in the frontline setting. Blood 141(21):2566\u20132575","journal-title":"Blood"},{"key":"6670_CR14","doi-asserted-by":"crossref","unstructured":"A predictive model for aggressive non-Hodgkin\u2019s lymphoma. N Engl J Med, (1993) 329(14): p. 987\u2013994","DOI":"10.1056\/NEJM199309303291402"},{"issue":"11","key":"6670_CR15","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1200\/JCO.20.02465","volume":"39","author":"F Merli","year":"2021","unstructured":"Merli F (2021) Simplified geriatric assessment in older patients with diffuse large B-Cell lymphoma: the prospective elderly project of the Fondazione Italiana linfomi. J Clin Oncol 39(11):1214\u20131222","journal-title":"J Clin Oncol"},{"issue":"1","key":"6670_CR16","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/s41408-023-00930-7","volume":"13","author":"J Jelicic","year":"2023","unstructured":"Jelicic J et al (2023) Prognostic indices in diffuse large B-cell lymphoma: a population-based comparison and validation study of multiple models. Blood Cancer J 13(1):157","journal-title":"Blood Cancer J"},{"issue":"4","key":"6670_CR17","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1093\/ajcn\/82.4.777","volume":"82","author":"O Bouillanne","year":"2005","unstructured":"Bouillanne O et al (2005) Geriatric nutritional risk index: a new index for evaluating at-risk elderly medical patients. Am J Clin Nutr 82(4):777\u2013783","journal-title":"Am J Clin Nutr"},{"key":"6670_CR18","doi-asserted-by":"publisher","DOI":"10.3389\/fnut.2023.1274592","volume":"10","author":"Q Yu","year":"2023","unstructured":"Yu Q et al (2023) Geriatric nutritional risk index as a predictor of prognosis in hematologic malignancies: a systematic review and meta-analysis. Front Nutr 10:1274592","journal-title":"Front Nutr"},{"issue":"5","key":"6670_CR19","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson ME (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40(5):373\u2013383","journal-title":"J Chronic Dis"},{"issue":"4","key":"6670_CR20","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1111\/j.1541-0420.2008.00995.x","volume":"64","author":"T Hothorn","year":"2008","unstructured":"Hothorn T, Zeileis A (2008) Generalized maximally selected statistics. Biometrics 64(4):1263\u20131269","journal-title":"Biometrics"},{"issue":"11","key":"6670_CR21","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1200\/JCO.20.02666","volume":"39","author":"L Oberic","year":"2021","unstructured":"Oberic L (2021) Subcutaneous Rituximab-MiniCHOP compared with subcutaneous Rituximab-MiniCHOP plus lenalidomide in diffuse large B-cell lymphoma for patients age 80 years or older. J Clin Oncol 39(11):1203\u20131213","journal-title":"J Clin Oncol"},{"issue":"1","key":"6670_CR22","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s41999-021-00539-8","volume":"13","author":"S Yamasaki","year":"2022","unstructured":"Yamasaki S et al (2022) Clinical impact of comprehensive geriatric assessment in patients aged 80 years and older with diffuse large B-cell lymphoma receiving rituximab-mini-CHOP: a single-institute retrospective study. Eur Geriatr Med 13(1):195\u2013201","journal-title":"Eur Geriatr Med"},{"key":"6670_CR23","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1169749","volume":"13","author":"D Cao","year":"2023","unstructured":"Cao D, Zhang Z (2023) Prognostic and clinicopathological role of geriatric nutritional risk index in patients with diffuse large B-cell lymphoma: a meta-analysis. Front Oncol 13:1169749","journal-title":"Front Oncol"},{"key":"6670_CR24","doi-asserted-by":"crossref","unstructured":"Chuang TM et al (2021) Low Geriatric Nutritional Risk Index Is Associated with Poorer Prognosis in Elderly Diffuse Large B-Cell Lymphoma Patients Unfit for Intensive Anthracycline-Containing Therapy: A Real-World Study. Nutrients, 13(9)","DOI":"10.3390\/nu13093243"},{"key":"6670_CR25","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.2147\/CIA.S313827","volume":"16","author":"Y Zhao","year":"2021","unstructured":"Zhao Y et al (2021) Association between geriatric nutritional risk index and frailty in older hospitalized patients. Clin Interv Aging 16:1241\u20131249","journal-title":"Clin Interv Aging"},{"issue":"1","key":"6670_CR26","doi-asserted-by":"publisher","first-page":"12493","DOI":"10.1038\/s41598-025-97769-8","volume":"15","author":"Q Qin","year":"2025","unstructured":"Qin Q, Li S, Yao J (2025) Association between the geriatric nutritional risk index with the risk of frailty and mortality in the elderly population. Sci Rep 15(1):12493","journal-title":"Sci Rep"},{"issue":"6","key":"6670_CR27","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1007\/s00277-018-3273-1","volume":"97","author":"Y Kanemasa","year":"2018","unstructured":"Kanemasa Y et al (2018) Geriatric nutritional risk index as a prognostic factor in patients with diffuse large B cell lymphoma. Ann Hematol 97(6):999\u20131007","journal-title":"Ann Hematol"},{"issue":"2","key":"6670_CR28","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1111\/j.1365-2141.2010.08331.x","volume":"151","author":"RH Advani","year":"2010","unstructured":"Advani RH (2010) Comparison of conventional prognostic indices in patients older than 60 years with diffuse large B-cell lymphoma treated with R-CHOP in the US intergroup study (ECOG 4494, CALGB 9793): consideration of age greater than 70 years in an elderly prognostic index (E-IPI). Br J Haematol 151(2):143\u2013151","journal-title":"Br J Haematol"},{"issue":"5","key":"6670_CR29","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1111\/bjh.18348","volume":"198","author":"M Picardi","year":"2022","unstructured":"Picardi M et al (2022) Liposomal doxorubicin supercharge-containing front-line treatment in patients with advanced-stage diffuse large B-cell lymphoma or classical hodgkin lymphoma: preliminary results of a single-centre phase II study. Br J Haematol 198(5):847\u2013860","journal-title":"Br J Haematol"},{"issue":"3","key":"6670_CR30","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.1002\/ehf2.13879","volume":"9","author":"A Cuomo","year":"2022","unstructured":"Cuomo A (2022) Impact of a cardio-oncology unit on prevention of cardiovascular events in cancer patients. ESC Heart Fail 9(3):1666\u20131676","journal-title":"ESC Heart Fail"},{"key":"6670_CR31","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14093257","author":"E Topa","year":"2025","unstructured":"Topa E et al (2025) Cardio-oncology challenges in elderly patients. J Clin Med. https:\/\/doi.org\/10.3390\/jcm14093257","journal-title":"J Clin Med"},{"issue":"22","key":"6670_CR32","doi-asserted-by":"publisher","first-page":"3488","DOI":"10.1182\/bloodadvances.2019000790","volume":"3","author":"BA Derman","year":"2019","unstructured":"Derman BA et al (2019) Results from a multidisciplinary clinic guided by geriatric assessment before stem cell transplantation in older adults. Blood Adv 3(22):3488\u20133498","journal-title":"Blood Adv"},{"issue":"17","key":"6670_CR33","doi-asserted-by":"publisher","first-page":"9991","DOI":"10.1073\/pnas.1732008100","volume":"100","author":"G Wright","year":"2003","unstructured":"Wright G et al (2003) A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc Natl Acad Sci USA 100(17):9991\u20139996","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6","key":"6670_CR34","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/j.clml.2014.05.002","volume":"14","author":"JA Read","year":"2014","unstructured":"Read JA (2014) Evaluating cell-of-origin subtype methods for predicting diffuse large B-cell lymphoma survival: a meta-analysis of gene expression profiling and immunohistochemistry algorithms. Clin Lymphoma Myeloma Leuk 14(6):460\u2013467e2","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"4","key":"6670_CR35","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1056\/NEJMoa2115304","volume":"386","author":"H Tilly","year":"2022","unstructured":"Tilly H et al (2022) Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma. N Engl J Med 386(4):351\u2013363","journal-title":"N Engl J Med"},{"issue":"10216","key":"6670_CR36","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1016\/S0140-6736(19)33008-9","volume":"394","author":"V Poeschel","year":"2019","unstructured":"Poeschel V et al (2019) Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial. Lancet 394(10216):2271\u20132281","journal-title":"Lancet"},{"issue":"26","key":"6670_CR37","doi-asserted-by":"publisher","first-page":"3003","DOI":"10.1200\/JCO.20.00999","volume":"38","author":"DO Persky","year":"2020","unstructured":"Persky DO (2020) Positron emission tomography-directed therapy for patients with limited-stage diffuse large B-cell lymphoma: results of intergroup National clinical trials network study S1001. J Clin Oncol 38(26):3003\u20133011","journal-title":"J Clin Oncol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06670-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-025-06670-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06670-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T02:31:09Z","timestamp":1764729069000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-025-06670-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,14]]},"references-count":37,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,11]]}},"alternative-id":["6670"],"URL":"https:\/\/doi.org\/10.1007\/s00277-025-06670-x","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-7351413\/v1","asserted-by":"object"}]},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,14]]},"assertion":[{"value":"12 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}